

Dongxia Gao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9843957/publications.pdf>

Version: 2024-02-01

26
papers

1,388
citations

623734

14
h-index

580821

25
g-index

26
all docs

26
docs citations

26
times ranked

3020
citing authors

#	ARTICLE	IF	CITATIONS
1	Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes. <i>Nature Communications</i> , 2022, 13, 896.	12.8	46
2	Abstract 5271: Correlative analysis of RNA biomarkers for adjuvant capecitabine benefit in the CIBOMA/2004-01 phase III clinical trial of triple negative breast cancer patients. <i>Cancer Research</i> , 2022, 82, 5271-5271.	0.9	0
3	Stroma vs epithelium-enhanced prognostics through histologic stratification in pancreatic ductal adenocarcinoma. <i>International Journal of Cancer</i> , 2021, 148, 481-491.	5.1	7
4	A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 557-566.	2.5	19
5	Granulocyte Colony Stimulating Factor Expression in Breast Cancer and Its Association with Carbonic Anhydrase IX and Immune Checkpoints. <i>Cancers</i> , 2021, 13, 1022.	3.7	6
6	Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 114.	5.2	3
7	The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine. <i>Oncolmmunology</i> , 2021, 10, 1924492.	4.6	8
8	Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms. <i>Cell Reports</i> , 2021, 37, 109817.	6.4	14
9	Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials. <i>Clinical Cancer Research</i> , 2021, 27, 6570-6579.	7.0	1
10	Prognostic Significance of CSF-1R Expression in Early Invasive Breast Cancer. <i>Cancers</i> , 2021, 13, 5769.	3.7	12
11	Phospho-Ser784-VCP Is Required for DNA Damage Response and Is Associated with Poor Prognosis of Chemotherapy-Treated Breast Cancer. <i>Cell Reports</i> , 2020, 31, 107745.	6.4	17
12	Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types. <i>Modern Pathology</i> , 2020, 33, 1753-1763.	5.5	25
13	Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. <i>Oncolmmunology</i> , 2020, 9, 1747340.	4.6	101
14	Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. <i>Modern Pathology</i> , 2019, 32, 1772-1785.	5.5	61
15	Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically. <i>Cancer Immunology Research</i> , 2019, 7, 1064-1078.	3.4	104
16	Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trial. <i>International Journal of Cancer</i> , 2019, 144, 2578-2586.	5.1	9
17	Nestin expression in breast cancer: association with prognosis and subtype on 3641 cases with long-term follow-up. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 107-115.	2.5	12
18	TIM-3 expression in breast cancer. <i>Oncolmmunology</i> , 2018, 7, e1502128.	4.6	42

#	ARTICLE	IF	CITATIONS
19	Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, e172085.	7.1	37
20	High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial. <i>Clinical Cancer Research</i> , 2017, 23, 946-953.	7.0	45
21	Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor. <i>Histopathology</i> , 2017, 70, 185-194.	2.9	13
22	Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. <i>BMC Cancer</i> , 2017, 17, 618.	2.6	42
23	Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. <i>Npj Breast Cancer</i> , 2016, 2, 16014.	5.2	109
24	Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 483-490.	2.5	30
25	An international study to increase concordance in Ki67 scoring. <i>Modern Pathology</i> , 2015, 28, 778-786.	5.5	195
26	PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer. <i>Cell Metabolism</i> , 2015, 22, 577-589.	16.2	430